Bin Xian Wei
Director/Board Member at PALISADE BIO, INC.
Net worth: 19 $ as of 2024-04-29
Bin Xian Wei active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PALISADE BIO, INC. | Director/Board Member | 2018-12-31 | - |
| Independent Dir/Board Member | - | - | |
| Dar Sheng Trade & Technic Development Co. Ltd. | Corporate Officer/Principal | 2014-12-31 | - |
Career history of Bin Xian Wei
Former positions of Bin Xian Wei
| Companies | Position | Start | End |
|---|---|---|---|
| SAKAI TRADING CO., LTD. | Corporate Officer/Principal | 2007-12-31 | 2009-12-31 |
| PALISADE BIO, INC. | Director/Board Member | 2019-02-04 | - |
| Independent Dir/Board Member | 2019-02-04 | - |
Training of Bin Xian Wei
| Tianjin University | Undergraduate Degree |
| Colorado School of Mines | Graduate Degree |
Statistics
International
| United States | 4 |
| China | 3 |
| Japan | 2 |
Operational
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PALISADE BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Sakai Trading Co., Ltd.
 Sakai Trading Co., Ltd. Wholesale DistributorsDistribution Services Sakai Trading Co., Ltd. engages in imports and exports chemical, synthetic resins and electronic materials. It operates through the Domestic and Overseas segments. The Domestic segment manages the domestic operations of the company's products. The Overseas segment handles the overseas operations through its subsidiaries located overseas. The company was founded February 10, 1936 and is headquartered in Osaka, Japan. | Distribution Services |
Seneca Biopharma, Inc.
 Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
| Dar Sheng Trade & Technic Development Co. Ltd. |
- Stock Market
- Insiders
- Bin Xian Wei
- Experience
